Increased ceramide in brains with alzheimer's and other neurodegenerative diseases

Journal of Alzheimer's Disease

Volumn 29, Issue 3, 2012, Pages 537-547

  Filippov, Valery ^a   Song, Minwoo Andrew ^a   Zhang, Kangling ^a   Vinters, Harry V ^b   Tung, Spencer ^b   Kirsch, Wolff M ^a   Yang, Jun ^c   Duerksen Hughes, Penelope J ^a  

^a LOMA LINDA UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; ceramide; neurodegeneration; sphingolipid biosynthesis; sphingolipid regulation

Indexed keywords

CERAMIDE; FATTY ACID; SPHINGOLIPID;

AGED; ALZHEIMER DISEASE; ARTICLE; ASMASE GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GALC GENE; GENE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIPID METABOLISM; LIPOGENESIS; MALE; NERVE CELL NECROSIS; NERVE DEGENERATION; NSMASE 2 GENE; PRIORITY JOURNAL; REGULATORY MECHANISM; UGCG GENE;

EID: 84859409865     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111202     Document Type: Article

References (23)

1. Scott KR, Barrett AM (2007) Dementia syndromes: Evaluation and treatment. Expert Rev Neurother 7, 407-422. (Pubitemid 46623362)
2. Jana A, Hogan EL, Pahan K (2009) Ceramide and neurode-generation: Susceptibility of neurons and oligodendrocytes to cell damage and death. J Neurol Sci 278, 5-15.
3. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101, 2070-2075. (Pubitemid 38229016)
4. Pettus BJ, Chalfant CE, Hannun YA (2002) Ceramideinapop-tosis: An overview and current perspectives. Biochim Biophys Acta 1585, 114-125.
5. Imgrund S, Hartmann D, Farwanah H, Eckhardt M, Sand-hoff R, Degen J, Gieselmann V, Sandhoff K, Willecke K (2009) Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. J Biol Chem 284, 33549-33560.
6. Haynes TA, Duerksen-Hughes PJ, Filippova M, Filippov V, Zhang K (2008) C18 ceramide analysis in mammalian cells employing reversed-phase high-performance liquid chro-matography tandem mass spectrometry. Anal Biochem 378, 80-86.
7. Kasumov T, Huang H, Chung YM, Zhang R, McCullough AJ, Kirwan JP (2010) Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Biochem 401, 154-161.
8. Zhang K, Haynes T-AS, Filippova M, Filippov V, Duerksen-Hughes PJ (2011) Quantification of ceramide levels in mammalian cells by high performance liquid chro-matography coupled to tandem mass spectrometry with multiple-reaction- monitoring mode (HPLC-MS/MS-MRM). Analytical Methods 3, 1193-1197.
9. He X, Huang Y, Li B, Gong CX, Schuchman EH (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31, 398-408.
10. Jennemann R, Sandhoff R, Wang S, Kiss E, Gretz N, Zuliani C, Martin-Villalba A, Jager R, Schorle H, Kenzelmann M, Bonrouhi M, Wiegandt H, Grone HJ (2005) Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc Natl Acad Sci USA 102, 12459-12464. (Pubitemid 41266381)
11. Laviad EL, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill AH Jr, Futerman AH (2008) Characterization of ceramide synthase 2: Tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 283, 5677-5684.
12. Colombaioni L, Garcia-Gil M (2004) Sphingolipid metabolites in neural signalling and function. Brain Res Brain Res Rev 46, 328-355. (Pubitemid 39574333)
13. van Echten-Deckert G, Herget T (2006) Sphingolipid metabolisminneural cells.Biochim Biophys Acta1758, 1978-1994.
14. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 89, 1671-1675.
15. Katsel P, Li C, Haroutunian V (2007) Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res 32, 845-856. (Pubitemid 46481322)
16. Mesicek J, Lee H, Feldman T, Jiang X, Skobeleva A, Berdy-shev EV, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2010) Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal 22, 1300-1307.
17. Marks N, Berg MJ, Saito M, Saito M (2008) Glucosylce-ramide synthase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: Consequences to morphology and viability on enzyme suppression in cultured primary neurons. Brain Res 1191, 136-147.
18. Kornhuber J, Medlin A, Bleich S, Jendrossek V, Henkel AW, Wiltfang J, Gulbins E (2005) High activity of acid sph-ingomyelinase in major depression. J Neural Transm 112, 1583-1590. (Pubitemid 41504272)
19. Jenkins RW, Canals D, Hannun YA (2009) Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 21, 836-846.
20. Hofmann K, Tomiuk S, Wolff G, Stoffel W (2000) Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci USA 97, 5895-5900. (Pubitemid 30367495)
21. Wu BX, Clarke CJ, Hannun YA (2010) Mammalian neutral sphingomyelinases: Regulation and roles in cell signaling responses. Neuromolecular Med 12, 320-330.
22. Zimmermann C, Ginis I, Furuya K, Klimanis D, Ruetzler C, Spatz M, Hallenbeck JM (2001) Lipopolysaccharide-induced ischemic tolerance is associated with increased levels of ceramide in brain and in plasma. Brain Res 895, 59-65. (Pubitemid 32231138)
23. de la Monte SM, Longato L, Tong M, DeNucci S, Wands JR (2009) The liver-brain axis of alcohol-mediated neurodegen-eration: Role of toxic lipids. Int J Environ Res Public Health 6, 2055-2075.